Skip to main content
SpringerLink
Log in

Cancers gynécologiques

Gynecological cancers

  • Compte Rendu / Report
  • Published:
Oncologie

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Références

  1. Bonomi P, Blessing JA, Stehman FB, et al. (1985) Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 3(8): 1079–85

    CAS  PubMed  Google Scholar 

  2. Burger RA, Brady MF, Bookman MA, et al. (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365(26): 2473–83

    Article  CAS  PubMed  Google Scholar 

  3. Degenhardt Y, Lampkin T (2010) Targeting Polo-like kinase in cancer therapy. Clin Cancer Res 16(2): 384–9

    Article  CAS  PubMed  Google Scholar 

  4. Du Bois A, Floquet A, Kim JW, et al. (2013) Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): results of an International Intergroup Trial (AGOOVAR16). J Clin Oncol 31(suppl; abstr LBA5503)

    Google Scholar 

  5. Jonathan A, Ledermann, Philipp Harter, et al. (2013) Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm). J Clin Oncol 31(suppl; abstr 5505)

    Google Scholar 

  6. Katsumata N, Yasuda M, Takahashi F, et al. (2009) Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomized controlled trial. Lancet 374(9698): 1331–8

    Article  CAS  PubMed  Google Scholar 

  7. Kehoe S, Hook J, Nankivell M, et al. (2013) Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: results from the MRC CHORUS trial. J Clin Oncol 31(suppl; abstr 5500)

    Google Scholar 

  8. Korach J, Colombo N, Davidenko I, et al. (2013) Feasibility and safety of front-line bevacizumab (BEV)-containing therapy after neoadjuvant (NA) chemotherapy (CT) for ovarian cancer (OC): the ROSIA experience. J Clin Oncol (suppl; abstr 5541)

    Google Scholar 

  9. Ledermann J, Harter P, Gourley C, et al. (2012) Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366(15): 1382–92

    Article  CAS  PubMed  Google Scholar 

  10. Long HJ 3rd, Bundy BN, Grendys EC Jr, et al. (2005) Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 23(21): 4626–33

    Article  CAS  PubMed  Google Scholar 

  11. Monk BJ, Sill MW, McMeekin DS, et al. (2009) Phase III trial of four cisplatincontaining doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 27(28): 4649–55

    Article  CAS  PubMed  Google Scholar 

  12. Pignata S, Scambia G, Lauria R, et al. (2013) A randomized multicenter phase III study comparing weekly versus every 3 weeks carboplatin (C) plus paclitaxel (P) in patients with advanced ovarian cancer (AOC): Multicenter Italian Trials in Ovarian Cancer (MITO-7) — European Network of Gynecological Oncological Trial Groups (ENGOT-ov-10) and Gynecologic Cancer Intergroup (GCIG) trial. J Clin Oncol 31(suppl; abstr LBA5501)

    Google Scholar 

  13. Press JZ, De Luca A, Boyd N, et al. (2008) Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 8: 17

    Article  PubMed Central  PubMed  Google Scholar 

  14. Pujade-Lauraine E, Weber BE, Ray-Coquard I, et al. (2013) Phase II trial of volasertib (BI 6727) versus chemotherapy (CT) in platinum-resistant/refractory ovarian cancer (OC). J Clin Oncol 31(suppl; abstr 5504)

    Google Scholar 

  15. Schöffski P, Awada A, Dumez H, et al. (2012) A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Eur J Cancer 48(2): 179–186

    Article  PubMed  Google Scholar 

  16. Tewari KS, Sill M, Long HJ, et al. (2013) Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. J Clin Oncol 31(suppl; abstr 3)

    Google Scholar 

  17. Thompson DS, Dudley BS, Bismayer JA, et al. (2013) Hainsworth. Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute. J Clin Oncol 31(suppl; abstr 5513)

    Google Scholar 

  18. Vergote I, Tropé CG, Amant F, et al. (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363(10): 943–953

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Département d’oncologie médicale, CLCC Paul-Strauss, 3, rue de la Porte-de-l’Hôpital, BP 42, F-67065, Strasbourg cedex, France

    T. Petit

Authors
  1. T. Petit
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Petit.

About this article

Cite this article

Petit, T. Cancers gynécologiques. Oncologie 15, 367–370 (2013). https://doi.org/10.1007/s10269-013-2307-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10269-013-2307-5

Search

Navigation